2:31 PM
 | 
May 10, 2018
 |  BC Innovations  |  Emerging Company Profile

Abac’s precision platform

How Abac’s pathogen-specific approach could reduce emergence of antibiotic resistance

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics.

The company’s PasNas platform uses phenotypic and in vitro assays to screen chemical libraries and identify pathogen-specific antibiotics for multidrug resistant microbes. According to CSO Domingo Gargallo-Viola, PasNas can identify candidates for any infectious microbial species, regardless of mechanism of action or molecular target, which are determined later in development.

PasNas uses an algorithm to select candidates based on 42 assays: 16 for efficacy, 16 for PK/PD properties and 10 for toxicity. Gargallo-Viola said this strategy eliminates potentially toxic candidates earlier in the drug discovery process, which is particularly important for antibiotics that often require doses in...

Read the full 585 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >